PuraPharm Corporation Limited has announced that its board of directors will convene on 26 August 2026. Key agenda items include:

• Review and approval of the Group’s interim results for the six months ended 30 June 2026. • Authorisation of the related results announcement for public release. • Deliberation on the declaration of an interim dividend, if deemed appropriate.

The meeting will be chaired by Executive Director and Chairman Chan Yu Ling, Abraham. The board currently comprises three executive directors, two non-executive directors and four independent non-executive directors, ensuring a diversified governance structure ahead of the forthcoming financial disclosures.